A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Other illness

• Have a known pre-existing, clinically important lung condition other than COPD.
• Have a current or recent acute, active infection before screening and up to randomization.

• Have a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD), at least 12 months prior to screening who meet the following criteria:
  • Current or former smokers with a smoking history of greater than or equal to (≥) 10 pack-years
  • Moderate-to-severe COPD (post-Bronchodilator (BD) Forced Expiratory Volume in 1 Second (FEV₁)/forced vital capacity (FVC) less than (\<) 70 percent (%)
  • Modified Medical Research Council Dyspnea Scale (mMRC-DS) grade ≥2
  • Exacerbation history of ≥2 moderate or ≥1 severe exacerbations within the year prior to inclusion.
  • Background double therapy \[long-acting β₂-agonists (LABA) + long-acting muscarinic antagonists (LAMA)\] or triple therapy \[inhaled corticosteroids (ICS) + LABA + LAMA)\] for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to screening.